



## PRESS RELEASE

Renee Brotherton  
Corporate Communications  
1 (408) 576-7189  
[renee.brotherton@flextronics.com](mailto:renee.brotherton@flextronics.com)

Kevin Kessel  
Investor Relations  
1 (408) 576-7985  
[kevin.kessel@flextronics.com](mailto:kevin.kessel@flextronics.com)

---

### **FLEXTRONICS PARTNERS WITH ICHOR MEDICAL SYSTEMS TO PROVIDE SUPPLY CHAIN SOLUTIONS, INCLUDING DESIGN AND MANUFACTURING SERVICES**

**San Jose, CA, May 7, 2014**—Flextronics (NASDAQ: FLEX), a leading end-to-end supply chain solutions company, announced that its Medical Group will provide design and manufacturing services to Ichor Medical Systems for the development of its next generation TriGrid™ DNA Delivery System, an electroporation device used to deliver DNA vaccines and treatments addressing a broad spectrum of disease indications. The TriGrid technology has recently been licensed by Pfizer for the intracellular delivery of their DNA-based cancer vaccines.

“Flextronics is proud to collaborate and provide supply chain solutions that include design and manufacturing for this exciting new technology,” said Mark Kemp, president of Flextronics Medical. “With the introduction of TriGrid electroporation, a wide range of promising DNA-based therapies can now be made much more effective. We applaud Ichor on their innovative work to advance therapies that lessen human disease and suffering. We look forward to helping them develop their product, from design to delivery.”

Supply chain services for this next generation TriGrid system will be performed at Flextronics facilities in Texas. Flextronics engineers will work with Ichor staff to develop and build the electronic and mechanical components of the device.

Ichor’s patented TriGrid Delivery System is the first integrated and fully automated device for electroporation-mediated DNA administration in humans. Electroporation is a potent method for enhancing DNA vaccine delivery with the application of electrical fields at the site of DNA administration, resulting in increased antigen expression and enhanced immune responses to the encoded antigen.

“Ichor is pleased to partner with a global organization like Flextronics,” said Ichor CEO, Bob Bernard. “Their dedication to quality and comprehensive solutions from design inputs to global distribution is a true asset to Ichor as we move toward rapid and scalable commercialization of the next generation TriGrid for novel DNA-based therapeutic products.”

By leveraging its proven manufacturing expertise across industries and established global scale, Flextronics can provide unique and innovative supply chain solutions for its customers’ most challenging needs.



## **PRESS RELEASE**

### **About Flextronics**

Flextronics (Reg. No. 199002645H) is a leading end-to-end supply chain solutions company that delivers design, engineering, manufacturing and logistics services to a range of industries and end-markets, including data networking, telecom, enterprise computing and storage, industrial, capital equipment, appliances, automation, medical, automotive, aerospace and defense, energy, mobile, computing and other electronic product categories. Flextronics is an industry leader with \$26 billion in sales, generated from helping customers design, build, ship, and service their products through an unparalleled network of facilities in approximately 30 countries and across four continents. Flextronics service offerings and vertically integrated component technologies optimize customer supply chains by lowering costs, increasing flexibility, and reducing time-to-market. For more information, visit [www.flextronics.com](http://www.flextronics.com) or follow us on Twitter @flextronics.

### **About Ichor Medical Systems**

Ichor Medical Systems, a privately-held biotech company based in San Diego, CA, provides its enabling TriGrid platform as a means for delivery of DNA drugs and vaccines in disease indications such as cancer, malaria, hepatitis B virus (HBV) infection, human immunodeficiency virus (HIV) infection, as well as for multiple biodefense agents. The TriGrid technology is presently utilized in over 15 clinical stage development products on 4 continents. For further information, visit <http://www.ichorms.com>.